--- title: "Atara Biotherapeutics (ATRA) news: class action and offering" url: "https://aibio.space/companies/atara-biotherapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ATRA class action and offering news: Atara Biotherapeutics faces securities class action over tab-cel ALLELE study statements. Atara Biotherapeutics, Inc." --- ATRA Atara Biotherapeutics, Inc. NASDAQ · United States # Atara Biotherapeutics (ATRA) news ATRA class action and offering news Legal · 2026-08-12 ## [Atara Biotherapeutics faces securities class action over tab-cel ALLELE study statements](https://aibio.space/news/atara-biotherapeutics-faces-securities-class-action-tab-cel-allele/) Kuang v. Atara, filed in Central District of California, names the company and unnamed current and former officers. An amended complaint came on August 10, and defendants must respond by October 9. ## Latest Atara Biotherapeutics news 1. 2025-05-15 Financings [Atara Biotherapeutics prices about $16.0 million registered direct offering at $6.61](https://aibio.space/news/atara-biotherapeutics-prices-about-16-0-million-registered-direct/) The deal includes 834,237 shares and pre-funded warrants for 1,587,108 more. Atara plans to use the money toward approval of tab-cel. 2. 2025-05-12 Distress [Atara Biotherapeutics cuts workforce by about 30%, expects $1.4 million in severance](https://aibio.space/news/atara-biotherapeutics-cuts-workforce-about-30-percent-expects-1-4/) The company will keep about 23 employees after the cut and expects about $1.4 million in severance. Its latest annual report said cash of $42.5 million would not last twelve months and that about $15 million more was needed to pursue US approval of its lead drug. ## Atara Biotherapeutics at a glance - **Ticker**: ATRA - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $9.9 million ### Related companies - [Nektar Therapeutics](https://aibio.space/companies/nektar-therapeutics/) NASDAQ: NKTR - [Ovid Therapeutics](https://aibio.space/companies/ovid-therapeutics/) NASDAQ: OVID - [BlossomHill Therapeutics](https://aibio.space/companies/blossomhill-therapeutics/) NASDAQ: BLSM - [Karyopharm Therapeutics](https://aibio.space/companies/karyopharm-therapeutics/) NASDAQ: KPTI - [Zevra Therapeutics](https://aibio.space/companies/zevra-therapeutics/) NASDAQ: ZVRA - [CTT Pharmaceutical Holdings](https://aibio.space/companies/ctt-pharmaceutical/) OTC: CTTH - [Indaptus Therapeutics](https://aibio.space/companies/indaptus-therapeutics/) NASDAQ: INDP - [Viridian Therapeutics](https://aibio.space/companies/viridian-therapeutics/) NASDAQ: VRDN ### Also on NASDAQ - [CASTLE BIOSCIENCES INC](https://aibio.space/companies/castle-biosciences/) CSTL - [Curanex Pharmaceuticals](https://aibio.space/companies/curanex-pharmaceuticals/) CURX - [AETHLON MEDICAL INC](https://aibio.space/companies/aethlon-medical/) AEMD - [Eledon Pharmaceuticals](https://aibio.space/companies/eledon-pharmaceuticals/) ELDN - [Alpha Cognition](https://aibio.space/companies/alpha-cognition/) ACOG - [NEUROONE MEDICAL TECHNOLOGIES](https://aibio.space/companies/neuroone-medical-technologies/) NMTC ## Atara Biotherapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$120.8 million](https://www.sec.gov/Archives/edgar/data/1604464/000119312526108361/) | [$128.9 million](https://www.sec.gov/Archives/edgar/data/1604464/000119312526108361/) | | Research and development | [$37.4 million](https://www.sec.gov/Archives/edgar/data/1604464/000119312526108361/) | [$151.5 million](https://www.sec.gov/Archives/edgar/data/1604464/000119312526108361/) | | Net income (loss) | [$32.7 million](https://www.sec.gov/Archives/edgar/data/1604464/000119312526108361/) | [-$85.4 million](https://www.sec.gov/Archives/edgar/data/1604464/000119312526108361/) | | Cash from operations | [-$50.9 million](https://www.sec.gov/Archives/edgar/data/1604464/000119312526108361/) | [-$68.7 million](https://www.sec.gov/Archives/edgar/data/1604464/000119312526108361/) | | Cash and equivalents | [$8.5 million](https://www.sec.gov/Archives/edgar/data/1604464/000119312526346885/) | [$25.0 million](https://www.sec.gov/Archives/edgar/data/1604464/000119312526108361/) | | Short-term investments | [$0](https://www.sec.gov/Archives/edgar/data/1604464/000119312526346885/) | [$17.5 million](https://www.sec.gov/Archives/edgar/data/1604464/000119312526108361/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $3.2 million, plus short-term investments of $6.7 million, $9.9 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Atara Biotherapeutics Is there a class action against Atara Biotherapeutics? Our latest story on this, dated Aug 12, 2026: "Atara Biotherapeutics faces securities class action over tab-cel ALLELE study statements". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/atara-biotherapeutics-faces-securities-class-action-tab-cel-allele/). Has Atara Biotherapeutics raised money recently? Our latest story on this, dated May 15, 2025: "Atara Biotherapeutics prices about $16.0 million registered direct offering at $6.61". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/atara-biotherapeutics-prices-about-16-0-million-registered-direct/). What is the ticker symbol of Atara Biotherapeutics? Atara Biotherapeutics, Inc. trades under the ticker ATRA on NASDAQ. Where is Atara Biotherapeutics listed? Atara Biotherapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:AT20; LSE:0HIY. What is the SEC CIK of Atara Biotherapeutics? The SEC Central Index Key (CIK) for Atara Biotherapeutics, Inc. is 1604464. Its filings are on SEC EDGAR. How many shares does Atara Biotherapeutics have outstanding? 10,037,710 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-12. Which country or territory is Atara Biotherapeutics listed under? Our directory records Atara Biotherapeutics, Inc. under United States. What does Atara Biotherapeutics do? Our directory classifies Atara Biotherapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Atara Biotherapeutics? The ISIN recorded for Atara Biotherapeutics, Inc. is US0465132068. Does aibio.space cover Atara Biotherapeutics? aibio.space lists Atara Biotherapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Atara Biotherapeutics incorporated? SEC records list its state or country of incorporation as DE. What was Atara Biotherapeutics's revenue last year? $120.8 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Atara Biotherapeutics profitable? Atara Biotherapeutics, Inc. reported net income of $32.7 million for the fiscal year ended Dec 31, 2025, and used $50.9 million of cash in operations, per its annual report to the SEC. How much does Atara Biotherapeutics spend on research and development? $37.4 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Atara Biotherapeutics have? $9.9 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. ## Investor discussion: Atara Biotherapeutics Members talk about Atara Biotherapeutics (ATRA). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Atara Biotherapeutics, newest first. Each line links the filing it comes from. 1. 2026-05-12 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1604464/000119312526219482/atra-20260331.htm) 2. 2026-05-12 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1604464/000119312526219518/atra-424-b5-2026_q2.htm) 3. 2026-05-01 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1604464/000119312526201397/atra-20260430.htm) 4. 2026-03-16 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1604464/000119312526108386/atra-424-b5-2026_q1.htm) 5. 2026-01-12 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1604464/000119312526010342/d34257dex991.htm) 6. 2025-10-07 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05). [Source](https://www.sec.gov/Archives/edgar/data/1604464/000119312525232117/d802811d8k.htm) 7. 2025-05-15 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1604464/000119312525120939/d892326d424b5.htm) 8. 2025-05-12 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05). [Source](https://www.sec.gov/Archives/edgar/data/1604464/000095017025069198/atra-20250512.htm) 9. 2025-03-03 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1604464/000095017025030832/atra-20250303.htm) 10. 2025-01-27 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1604464/000095017025009225/atra-20250127.htm) 11. 2024-11-12 Distress Reported a leadership departure tied to a disagreement or a restructuring. SEC Form 8-K (Items 2.02,5.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1604464/000095017024125334/atra-ex99_1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ATRA on TradingView](https://www.tradingview.com/symbols/NASDAQ-ATRA/). ## SEC filings and registration - **SEC name**: Atara Biotherapeutics, Inc. - **CIK**: 1604464 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: ATRA (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA, 91320 - **Phone**: 805-623-4211 - **Shares outstanding**: 10,037,710 as of 2026-08-10 (10-Q filed 2026-08-12) ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1604464/000119312526346885/atra-20260630.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1604464/000119312526346857/atra-20260812.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1604464/000119312526285498/atra-20260622.htm) filed 2026-06-26 - [8-K](https://www.sec.gov/Archives/edgar/data/1604464/000121390026068264/ea0294561-8k_atara.htm) filed 2026-06-12 - [424B5](https://www.sec.gov/Archives/edgar/data/1604464/000119312526219518/atra-424-b5-2026_q2.htm) filed 2026-05-12 - [10-Q](https://www.sec.gov/Archives/edgar/data/1604464/000119312526219482/atra-20260331.htm) filed 2026-05-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1604464/000119312526219420/atra-20260512.htm) filed 2026-05-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1604464/000119312526210413/atra-20260507.htm) filed 2026-05-07 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001604464), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Atara Biotherapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ATRA, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Atara Biotherapeutics, Inc. - **Ticker**: ATRA - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US0465132068 - **Other listed symbols**: GETTEX:AT20; LSE:0HIY - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ATRA/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/atara-biotherapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Atara Biotherapeutics (ATRA) news: class action and offering", 2026-10-31, https://aibio.space/companies/atara-biotherapeutics/